DNA Script
DNA Script engineers biology to revolutionize DNA writing with enzymes, providing in-house DNA synthesis capabilities for labs through integrated enzyme engineering and instrumentation.
Classification
Profile
Funding
Funding details not yet available.
In-house DNA synthesis using engineered enzymes to provide labs with reliable, overnight ssDNA oligo production and complete autonomy.
Life science and human health research labs requiring reliable, fast, and easy-to-use in-house DNA writing capabilities.
Direct sales of proprietary enzyme engineering technology, nucleotide chemistries, and integrated instrumentation for in-house use.
Direct sales motion targeting labs and organizations seeking to eliminate uncertainty and retain control over their DNA synthesis projects.
BaseClick GmbH - exclusive license for modified-DNA printing technology[2] · Illumina Ventures & Other Biotech Investors - provide capital and market access · Regional Distributors (e.g., in Japan, Middle East) - extend market penetration
Core R&D efforts focused on enzyme engineering, surface and nucleotide chemistries, and instrumentation development.
Proprietary enzyme engineering innovations, surface/nucleotide chemistries, integrated instrumentation, and specialized leadership team.
Engineering biology to revolutionize DNA writing through R&D in enzymes, chemistries, and instrumentation for life science applications.
Sales-led engagement focused on providing reliability, speed, and ease to labs wanting to own their synthesis capability.
Competes by enabling in-house synthesis via enzyme engineering, contrasting with traditional chemical synthesis providers by offering autonomy and speed.
Eliminates uncertainty and lack of control in DNA synthesis projects by providing overnight, high-quality ssDNA oligos with complete autonomy.
- Introduce a Consumable Subscription Model - Offer tiered reagent bundles (e.g., “Starter”, “Growth”, “Enterprise”) with automatic repleni
Map existing customers to the subscription tiers - identify high-frequency reagent purchasers and pilot the bundle program · Run a social-listening sprint on X, LinkedIn, and niche forums (e.g., SeqAnswers) to quantify the volume of “lead-time” vs. “cost” pain ment · Negotiate additional OEM partnerships in emerging biotech hubs (e.g., Shenzhen, Ba
Hardware sales → Consumable revenue - each SYNTAX unit creates a locked-in demand for reagents (razor-blade) · Key Partnerships ↔ Revenue Streams - licensing deals (BaseClick) and distribution agreements directly open new income channels · Customer Segments ↔ Value Propositions - academic labs value speed and low waste; pharma values fidelity and r
Team details not yet available.
No investors recorded yet.